ABSTRACT
A series of imidazolinylindole derivatives were discovered as novel kallikrein 7 (KLK7, stratum corneum chymotryptic enzyme) inhibitors. Structure-activity relationship (SAR) studies led to the identification of potent human KLK7 inhibitors. By further modification of the benzenesulfonyl moiety to overcome species differences in inhibitory activity, potent inhibitors against both human and mouse KLK7 were identified. Furthermore, the complex structure of 25 with mouse KLK7 could explain the SAR and the cause of the species differences in inhibitory activity.
Subject(s)
Drug Discovery , Enzyme Inhibitors/pharmacology , Imidazolines/pharmacology , Indoles/pharmacology , Kallikreins/antagonists & inhibitors , Animals , Dose-Response Relationship, Drug , Enzyme Inhibitors/chemical synthesis , Enzyme Inhibitors/chemistry , Humans , Imidazolines/chemical synthesis , Imidazolines/chemistry , Indoles/chemical synthesis , Indoles/chemistry , Kallikreins/metabolism , Mice , Molecular Structure , Structure-Activity RelationshipABSTRACT
A series of 1,3,6-trisubstituted 1,4-diazepan-7-ones were prepared as kallikrein 7 (KLK7, stratum corneum chymotryptic enzyme) inhibitors. Previously reported compounds 1-3 were potent human KLK7 inhibitors; however, they did not exhibit inhibitory activity against mouse KLK7. Comparison of the human and mouse KLK7 structures reveals the cause of this species differences; therefore, compounds that could inhibit both KLK7s were designed, synthesized, and evaluated. Through this structure-based drug design, compound 22g was identified as an inhibitor against human and mouse KLK7, and only one of the enantiomers, (-)-22g, exhibited potent inhibitory activity. Furthermore, the crystal structure of mouse KLK7 complexed with 22g enabled the elucidation of structure-activity relationships and justified 22g as a valuable compound to overcome the species differences.
Subject(s)
Azepines/chemistry , Kallikreins/metabolism , Protease Inhibitors/chemical synthesis , Amino Acid Sequence , Animals , Azepines/metabolism , Binding Sites , Crystallography, X-Ray , Drug Design , Humans , Kallikreins/antagonists & inhibitors , Mice , Protease Inhibitors/metabolism , Protein Structure, Tertiary , Sequence Alignment , Species Specificity , Stereoisomerism , Structure-Activity RelationshipABSTRACT
A novel series of 1,3,6-trisubstituted 1,4-diazepan-7-ones were investigated as human kallikrein 7 (KLK7, stratum corneum chymotryptic enzyme) inhibitors. Based on the X-ray co-crystal structure of compound 1 bound to human KLK7, the derivatives of this scaffold were designed, synthesized, and evaluated. Through structure-activity relationship studies focused on the side chain located in the prime site region of the enzyme, representative compounds 15, 33a, and 35a were identified as highly potent and selective inhibitors of human KLK7.
Subject(s)
Azepines/pharmacology , Kallikreins/antagonists & inhibitors , Azepines/chemical synthesis , Azepines/chemistry , Binding Sites , Crystallography, X-Ray , Drug Design , Humans , Kallikreins/chemistry , Molecular Docking Simulation , Molecular Structure , Stereoisomerism , Structure-Activity RelationshipABSTRACT
Based on insight from the X-ray crystal structure of human chymase in complex with compound 1, a lactam carbonyl of the diazepane core was exchanged with O-substituted oxyimino group, leading to amidoxime derivatives. This modification resulted in highly potent chymase inhibitors, such as O-phenylamidoxime 5f. X-ray crystal structure analysis indicated that compound 5f induced movement of the Leu99 and Tyr94 side chains at the S2 site, and the increase in inhibitory activity of O-phenyl amidoxime derivatives suggested that the O-phenyl moiety interacted with the Tyr94 residue. Surface plasmon resonance experiments showed that compound 5f had slower association and dissociation kinetics and the calculated residence time of compound 5f to human chymase was extended compared to that of amide compound 1.
Subject(s)
Chymases/antagonists & inhibitors , Drug Design , Oximes/pharmacology , Serine Proteinase Inhibitors/pharmacology , Binding Sites/drug effects , Chymases/metabolism , Dose-Response Relationship, Drug , Humans , Molecular Structure , Oximes/chemical synthesis , Oximes/chemistry , Serine Proteinase Inhibitors/chemical synthesis , Serine Proteinase Inhibitors/chemistry , Structure-Activity RelationshipABSTRACT
Compound 1, composed of a 1,3,6-trisubstituted 1,4-diazepane-7-one, was discovered as a novel human kallikrein 7 (KLK7, stratum corneum chymotryptic enzyme, SCCE) inhibitor, and its derivatives were synthesized and evaluated. Structure-activity relationship studies of the amidoxime unit and benzoic acid part of this new scaffold led to the identification of 25 and 34, which were more potent than the hit compound, 1. The X-ray co-crystal structure of compound 25 and human KLK7 revealed the characteristic interactions and enabled explanations of the structure-activity relationship.
Subject(s)
Azepines/pharmacology , Drug Discovery , Kallikreins/antagonists & inhibitors , Serine Proteinase Inhibitors/pharmacology , Azepines/chemical synthesis , Azepines/chemistry , Dose-Response Relationship, Drug , Humans , Kallikreins/metabolism , Molecular Structure , Serine Proteinase Inhibitors/chemical synthesis , Serine Proteinase Inhibitors/chemistry , Structure-Activity RelationshipABSTRACT
Protein tyrosine phosphatase receptor-type Z (PTPRZ) is aberrantly over-expressed in glioblastoma and a causative factor for its malignancy. However, small molecules that selectively inhibit the catalytic activity of PTPRZ have not been discovered. We herein performed an in vitro screening of a chemical library, and identified SCB4380 as the first potent inhibitor for PTPRZ. The stoichiometric binding of SCB4380 to the catalytic pocket was demonstrated by biochemical and mass spectrometric analyses. We determined the crystal structure of the catalytic domain of PTPRZ, and the structural basis of the binding of SCB4380 elucidated by a molecular docking method was validated by site-directed mutagenesis studies. The intracellular delivery of SCB4380 by liposome carriers inhibited PTPRZ activity in C6 glioblastoma cells, and thereby suppressed their migration and proliferation in vitro and tumor growth in a rat allograft model. Therefore, selective inhibition of PTPRZ represents a promising approach for glioma therapy.
Subject(s)
Enzyme Inhibitors , Glioblastoma , Molecular Docking Simulation , Neoplasm Proteins , Neoplasms, Experimental , Receptor-Like Protein Tyrosine Phosphatases, Class 5 , Animals , Cell Line, Tumor , Crystallography, X-Ray , Enzyme Inhibitors/chemistry , Enzyme Inhibitors/pharmacology , Glioblastoma/drug therapy , Glioblastoma/enzymology , Glioblastoma/genetics , Male , Mutagenesis, Site-Directed , Neoplasm Proteins/antagonists & inhibitors , Neoplasm Proteins/chemistry , Neoplasm Proteins/genetics , Neoplasm Proteins/metabolism , Neoplasms, Experimental/drug therapy , Neoplasms, Experimental/enzymology , Neoplasms, Experimental/genetics , Rats , Rats, Wistar , Receptor-Like Protein Tyrosine Phosphatases, Class 5/antagonists & inhibitors , Receptor-Like Protein Tyrosine Phosphatases, Class 5/chemistry , Receptor-Like Protein Tyrosine Phosphatases, Class 5/genetics , Receptor-Like Protein Tyrosine Phosphatases, Class 5/metabolismABSTRACT
A novel series of 6-benzyl substituted 4-aminocarbonyl-1,4-diazepane-2,5-diones were explored as human chymase inhibitors using structure-based drug design according to the X-ray cocrystal structure of chymase and compound 1. The optimization focused on the prime site led to the attainment of compounds that showed potent inhibitory activity, and among them, 18R shows a novel interaction mode.
Subject(s)
Azepines/chemical synthesis , Chymases/antagonists & inhibitors , Drug Design , Enzyme Inhibitors/chemistry , Ethylmorphine/chemical synthesis , Azepines/chemistry , Azepines/pharmacology , Catalytic Domain , Crystallography, X-Ray , Enzyme Activation/drug effects , Enzyme Inhibitors/pharmacology , Ethylmorphine/chemistry , Ethylmorphine/pharmacology , Humans , Inhibitory Concentration 50 , Molecular Structure , Structure-Activity RelationshipABSTRACT
A series of truncated analogs of α-galactosylceramide with altered ceramide moiety was prepared, and evaluated for Th2-biased response in the context of IL-4/IFN-γ ratio. Phytosphingosine-modified analogs including cyclic, aromatic and ethereal compounds as well as the C-glycoside analog of OCH (2) with their cytokine inducing profile are disclosed.
Subject(s)
Galactosylceramides/chemistry , Galactosylceramides/pharmacology , Gene Expression Regulation/drug effects , Interferon-gamma/metabolism , Interleukin-4/metabolism , Animals , Antigens, CD1d/chemistry , Antigens, CD1d/metabolism , Binding Sites , Computer Simulation , Galactosylceramides/chemical synthesis , Mice , Mice, Inbred C57BL , Th2 Cells/drug effectsABSTRACT
Analogs of immunomodulatory glycolipid OCH (2) were prepared and minimum structure requirement to exhibit equivalent profiles was disclosed. Analogs bearing non-linear hydrocarbon chain in the phytosphingosine moiety (18, 19) were shown for the first time to possess comparable cytokine inducing profile to 2. Molecular modeling of 2/hCD1d complex based on the crystal structure of alpha-GalCer (1)/hCD1d complex is also described.
Subject(s)
Cytokines/metabolism , Glycolipids/metabolism , Immunologic Factors/metabolism , Sphingosine/analogs & derivatives , Th2 Cells/metabolism , Animals , Humans , Molecular Structure , Sphingosine/chemistryABSTRACT
A novel series of 6-substituted 4-sulfonyl-1,4-diazepane-2,5-diones were designed, synthesized and evaluated as human chymase inhibitors. Structure-activity relationship studies led to the identification of a potent inhibitor, (6S)-6-(5-chloro-2-methoxybenzyl)-4-[(4-chlorophenyl)sulfonyl]-1,4-diazepane-2,5-dione, with an IC(50) of 0.027 microM.
Subject(s)
Azepines/pharmacology , Chymases/antagonists & inhibitors , Serine Proteinase Inhibitors/pharmacology , Azepines/chemical synthesis , Humans , Inhibitory Concentration 50 , Models, Chemical , Serine Proteinase Inhibitors/chemical synthesis , Structure-Activity RelationshipABSTRACT
A novel series of 6-benzyl substituted 4-aminocarbonyl-1,4-diazepane-2,5-diones was designed, synthesized, and evaluated as human chymase inhibitors. From this series, we identified several compounds which were effective, via oral administration, in a mouse model of chronic dermatitis.
Subject(s)
Azepines/pharmacology , Benzyl Compounds/pharmacology , Chymases/antagonists & inhibitors , Dermatitis/drug therapy , Serine Proteinase Inhibitors/pharmacology , Administration, Oral , Animals , Azepines/chemical synthesis , Benzyl Compounds/chemical synthesis , Binding Sites , Dermatitis/pathology , Disease Models, Animal , Humans , Inhibitory Concentration 50 , Mice , Models, Chemical , Serine Proteinase Inhibitors/chemical synthesis , Serine Proteinase Inhibitors/therapeutic use , Structure-Activity RelationshipABSTRACT
The ability to convert angiotensin (Ang) I to Ang II was compared between human alpha-chymase and two mouse beta-chymases, mouse mast cell protease (mMCP)-1 and mMCP-4. Human chymase hydrolyzed Ang I to produce Ang II without further degradation. mMCP-1 similarly generated Ang II from Ang I in a time-dependent manner and the formation of the fragment other than Ang II was marginal. In contrast, mMCP-4 hydrolyzed Ang I at two sites, Tyr(4)-Ile(5) and Phe(8)-His(9), with Ang II formation being tentative. Consistently, mMCP-4 but not human chymase hydrolyzed Ang II and mMCP-1 showed little hydrolytic activity against Ang II. These data suggest that not only human chymase but also mMCP-1 might possess a physiological role in Ang II formation. Our findings also imply that the Ang-converting activity of chymase may not be related to the categorization of chymase into alpha- or beta-type based on their primary structure.
Subject(s)
Angiotensin II/metabolism , Angiotensin I/metabolism , Serine Endopeptidases/metabolism , Animals , Chromatography, High Pressure Liquid , Chymases , Humans , MiceABSTRACT
A series of novel 4-arylpiperidines and 4-aryl-4-piperidinols (2a-f, 3a-f and 4a-f) was synthesized and evaluated for blocking effects on both neuronal Na(+) and T-type Ca(2+) channels and binding affinity for dopamine D(2) receptors. Most of the compounds blockaded both ion channels with potency greater than or equal to flunarizine 1a which was adopted as a reference standard. In addition, these compounds had significantly reduced affinity for dopamine D(2) receptors which is common in this class of structure. Compounds 2a-f, 3a-f and 4a-f exhibited potent anticonvulsant effects following systemic (ip) administration on audiogenic seizures in DBA/2 mice, indicating their excellent brain permeability. The neuroprotective activity of 2a, 3a and 4a was also assessed in a transient middle cerebral artery occlusion (MCAO) model. These compounds significantly reduced neuronal damage without affecting ischemic hyperthemia, while flunarizine 1a produced only minor reductions. In particular, 4a had 1.7-fold the potency in this MCAO model but only 1/20 the affinity for dopamine D(2) receptors of 1a. The superposition of 2a, 3a and 4a on the basis of analyses of systematic conformation and similar structure has revealed that the cinnamyl, phenacyl and phenoxypropanol groups are likely to be structurally and biologically equivalent. Moreover, the superposition of 2a and 2f shows that diphenyl ether and biphenyl groups occupy a similar space, suggesting that both groups act as a bioisostere for the blockade of ion channels; however, this is not the case for dopamine D(2) receptors since only biphenyl compounds such as 2f had high affinity similar to flunarizine 1a. Compound 4a (SUN N5030) has a good pharmacological profile and may be useful in the alleviation and treatment of ischemic diseases.